Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influence of an Acidic Beverage (Coca-Cola) on the exposure to Imatinib (GLIvec) after major gastrecTomY in patients with Gastrointestinal Stromal Tumors (ABILITY)

Next Previous
Trial Profile

Influence of an Acidic Beverage (Coca-Cola) on the exposure to Imatinib (GLIvec) after major gastrecTomY in patients with Gastrointestinal Stromal Tumors (ABILITY)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Adverse reactions
  • Acronyms ABILITY

Most Recent Events

  • 28 Jul 2023 According to a Medicenna Therapeutics Media Release, initial data from ABILITYs fifth and sixth dose escalation cohorts will be presented in Q3 2023.Commencement of the ABILITY studys MDNA11 Phase 2 monotherapy arm expected in calendar Q3 2023 and Clinical update expected in calendar Q4 2023.
  • 28 Jul 2023 According to a Medicenna Therapeutics Media Release,the company will host a conference call on 9 th Aug 2023 to discuss data from cohorts five and six, recommended dose for monotherapy expansion and details on Phase 2 trial design.
  • 28 Jul 2023 According to a Medicenna Therapeutics Media Release, Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study.$29.6 million in cash and cash equivalents as of June 30, 2023 provides expected runway through the completion of the ABILITY study and through calendar Q3 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top